九洲药业：子公司浙江九洲药物科技有限公司通过美国FDA现场检查

Core Viewpoint - The company, Jiuzhou Pharmaceutical, announced that its subsidiary, Zhejiang Jiuzhou Pharmaceutical Technology Co., Ltd., successfully passed the cGMP on-site inspection by the FDA, which will support its expansion into international markets [1] Group 1 - The FDA inspection took place from March 17 to March 21, 2025, covering six major systems [1] - The successful completion of the cGMP inspection indicates compliance with FDA standards, enhancing the company's credibility in the global market [1] - This achievement is expected to positively influence the company's efforts to expand into regulated international markets [1]